Kiora Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stock-Based Compensation (Tables)

Stock-Based Compensation (Tables)

6 Months Ended

Jun. 30, 2022

Equity Incentive Plan

Schedule of stock-based compensation expense


		Three months ended June 30						Six months ended June 30
		2022			2021			2022			2021
Research and Development		$	26,540		$	69,219			59,160			140,805
General and Administrative			44,714			193,673			228,015			339,032
Total Stock-Based Compensation Expense		$	71,254		$	262,892			287,175			479,837

Schedule of weighted average assumptions


		2022			2021
Risk-Free Interest Rate		2.42	%		1.82	%
Expected Life (years)		5.00			10.00
Expected Stock Price Volatility		140	%		141	%
Expected Dividend Yield		—	%		—	%

Schedule of stock option activity


							Weighted-Average
		Number of		Weighted- Average			Remaining
		Options		Exercise Price			Term in Years
Outstanding at December 31, 2021		515,922		$	10.43		8.30
Granted		260,500		$	0.76		9.60
Expired		(138,526)		$	18.42
Forfeited		(115,830)		$	2.65
Outstanding at June 30, 2022		522,066		$	5.34		8.73
Exercisable and vested at June 30, 2022		123,271		$	16.69		6.72

Outstanding at December 31, 2020		246,893		$	20.90		7.20
Granted		150,365		$	6.19
Expired		(7,599)		$	10.82
Forfeited		(12,298)		$	6.51
Outstanding at June 30, 2021		377,361		$	15.71		7.82
Exercisable and vested at June 30, 2021		198,822		$	24.25		6.46

Schedule of restricted stock activity


							Weighted- Average
		Number of		Weighted- Average			Remaining
		Units		Grant Date Fair Value			Term in Years
Non-vested at December 31, 2021		15,012		$	6.55		1.09
Vested		(9,781)		$	6.55
Forfeited		(5,097)		$	6.55
Non-vested at June 30, 2022		134		$	6.55		0.59

Non-vested Outstanding at December 31, 2020		67,420		$	7.10		1.66
Vested		(37,041)		$	7.39
Forfeited		(2,051)		$	6.86
Non-vested Outstanding at June 30, 2021		28,328		$	6.73		1.59